J&J, Novavax post phase 3 data To view this email as a web page,
click here | | Webinar: 2021 Apollo Healthcare Predictions Thursday, February 4, 2021 | 1pm ET / 10am PT With so much disruption from COVID-19, this year’s global insights will provide a unique window into the minds of those professionals perhaps most tested by 2020 and their hopes and perspectives for 2021. Register Now! |
AstraZeneca's COVID-19 shot scores European authorization as production holdups linger J&J single shot sees 66% efficacy in moderate COVID-19, 85% in severe cases; shares fall Novavax COVID-19 vaccine 90% efficacious in phase 3, but protection plummets against one variant New MGMA, Humana report highlights impact of care deferred due to COVID-19 WHO shepherds $2.50-per-test deal to support rapid COVID-19 screening in low-resource countries Novartis pitches in to help produce Pfizer/BioNTech COVID-19 vaccine Malcolm Gladwell says COVID-19 pandemic has one notable 'winner': science Eli Lilly's COVID-19 antibody picks up $871M in Q4—and carries blockbuster hopes for 2021 UPDATED Coronavirus tracker: Fauci says U.K. variants expected to be dominant in U.S. by March One-dose COVID-19 vaccine candidate that can be stored at room temperature prompts immunity in animals Featured Story | By Eric Sagonowsky After months of research and a week-long controversy over a reduction in expected vaccine supply, regulators in Europe have authorized AstraZeneca’s two-dose COVID-19 vaccine. read more |
| |
|---|
|
Top Stories By Ben Adams Johnson & Johnson saw its shares fall 4% in early trading on the news that its one-shot COVID-19 vaccine saw 66% efficacy in moderate to severe disease, rising to 85% in severe disease. read more By Nick Paul Taylor Novavax’s COVID-19 vaccine has achieved 89.3% efficacy in a phase 3 clinical trial that enrolled subjects exposed to the B.1.1.7 variant found in the U.K. However, the vaccine performed far worse in a smaller phase 2b that pitted it against another variant first identified in South Africa, intensifying concerns that updated prophylactics will be needed to protect against the evolving virus. read more By Paige Minemyer The first wave of care deferrals offers lessons in managing the impacts of the current surge, according to a new report. read more By Conor Hale The agreement with Premier Medical Corporation, based in India, aims to deliver at least 250 million rapid antigen test kits for less than $2.50 apiece. read more By Eric Sagonowsky Only a day after Novartis said it was looking at offering its manufacturing network to the global COVID-19 fight, the company is joining forces with Pfizer and BioNTech to help produce mRNA vaccines. It's the latest example of an unlikely Big Pharma partnership spurred by the urgent need to defeat the pandemic. read more By Paige Minemyer Author and journalist Malcolm Gladwell said that if there are any bright spots coming out of the COVID-19 pandemic, it's the public's growing faith in science. read more By Eric Sagonowsky Eli Lilly's COVID-19 antibody stole the show during the fourth quarter, and the company says there's more to come as the U.S. government just placed another big order—and Lilly itself projects blockbuster coronavirus revenues in 2021. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Arlene Weintraub Two COVID-19 vaccine candidates built from gene therapy technology elicited strong immune responses in mouse and nonhuman primate models. The Mass General scientists who developed the vaccines believe their ability to be stored at room temperature and to be administered in just one dose could make them popular choices for developing countries. read more |
|
